Disrupting the CD47-SIRPα axis using mAbs has been shown to increase the phagocytosis against cancer cells and inhibit the progression of some hematological malignancies as well as solid tumors18,21,49,50. The gene discussed is SIRPA; the disease is hematologic disorder.